

### **AMENDMENT OF THE CLAIMS**

Please amend the claims as follows. This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A method to reduce recruitment of IDO+ dendritic cells that inhibit T-cell proliferation to at least one of a tumor or a tumor-draining lymph node in a subject comprising administering a composition comprising an antibody to CCR6 to the subject to reduce recruitment of the IDO+ dendritic cells to the at least one of a tumor or a tumor-draining lymph node, wherein the IDO+ dendritic cells express CCR6 and elevated levels of indoleamine 2,3-dioxygenase (IDO) (~~IDO~~), and tumor cells of the at least one of a tumor or a tumor draining lymph node express MIP-3 $\alpha$ .
2. (Canceled)
3. (Original) The method of claim 1, wherein the subject is human.
4. (Previously presented) The method of claim 1, wherein the CCR6 antibody blocks the interaction between the CCR6 expressed by the IDO+ dendritic cells and the MIP-3 $\alpha$  expressed by tumor cells of the at least one of a tumor or a tumor draining lymph node.
5. (Previously presented) The method of claim 1, further comprising the step of determining that IDO+ dendritic cells are recruited to the at least one of a tumor or a tumor-draining lymph node.
6. (Previously presented) The method of claim 1, wherein the MIP-3 $\alpha$  mediates recruitment of the IDO+ dendritic cells to the at least one of a tumor or a tumor draining lymph node.

Claims 7-48 (Canceled)